1
Foote Kevin Michael, Griffen Edward Jolyon: Indole derivatives. Astrazeneca, Astrazeneca, Foote Kevin Michael, Griffen Edward Jolyon, GLOBAL INTELLECTUAL PROPERTY, November 29, 2007: WO/2007/135398 (66 worldwide citation)

The invention concerns indole derivatives of Formula (I) or pharmaceutically-acceptable salts thereof, wherein each of Ring A, m, R1, R2, n, R3 and G1 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and the ...


2
HAN AMY QI: Antiviral pyrimidines. PROGENICS PHARMACEUTICALS, Moore Steven J, October 14, 2010: WO/2010/118367 (43 worldwide citation)

Disclosed herein are novel compounds comprising substituted pyrimidines, pyrazolopyrimtdines, and imidazolopyrimidines, the syntheses thereof, and compositions thereof, including pharmaceutical compositions, comprising the novel pyrimidines, pyrazolopyrimtdines, imidazolpyrimidines and related compo ...


3

4
Galemmo Robert Anthony Jr, Dominguez Celia, Fevig John Matthew, Han Qi, Lam Patrick Yuk Sun, Pinto Donald Joseph Philip, Pruitt James Russell, Quan Mimi Lifen: Inhibitors of factor xa with a neutral p1 specificity group. Du Pont Merck Pharma, April 12, 2000: EP0991625-A2 (32 worldwide citation)

The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula (I) or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.


5
Brian E Ledford: Inhibitors of JAK and CDK2 protein kinases. Vertex Pharmaceuticals Incorporated, Karen E Brown, Vertex Pharmaceutical Incorporated, October 17, 2006: US07122552 (31 worldwide citation)

The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of JAK and CDK2 mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising ...


6
Kshirsagar Tushar A, Merrill Bryon A, Niwas Shri, Lundquist Gregory D Jr, Heppner Philip D, Danielson Michael E: Hydroxyalkyl substituted imidazoquinoline compounds and methods. Coley Pharmaceutical Group, Kshirsagar Tushar A, Merrill Bryon A, Niwas Shri, Lundquist Gregory D Jr, Heppner Philip D, Danielson Michael E, GATES Edward R, August 31, 2006: WO/2006/091567 (28 worldwide citation)

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, and an aryl or heteroaryl substituent at the 7-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for ...


7

8
Doria Gianfederico, Isetta Anna Maria, Ferrari Mario, Trizio Domenico: Condensed pyrazole 3-oxo-propanenitrile derivatives and process for their preparation.. Erba Carlo, December 27, 1989: EP0347773-A1 (25 worldwide citation)

Condensed pyrazole 3-oxo-propanenitrile derivatives of formula (I) wherein X represents a - CH(R4)-group, an oxygen atom or a - S(O)n- group where n is 0, 1 or 2; R1 represents C1-C6 alkyl, pyridyl or unsubstituted or substituted phenyl; R2, R3 and R4 are as defined herein; and Q represents hydrogen ...


9
Karnail S Atwal, Wayne Vaccaro, John Lloyd, Heather Finlay, Lin Yan, Rao S Bhandaru: Heterocyclic dihydropyrimidine compounds. Bristol Myers Squibb Company, Terence J Bogie, Maureen P O Brien, January 2, 2007: US07157451 (24 worldwide citation)

Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of ...


10
Cornelia J Forster, Larry C Park, Marion W Wannamaker, Yung Mae M Yao: Compositions useful as inhibitors of GSK-3. Vertex Pharmaceuticals Incorporated, Jennifer G Che, January 18, 2011: US07872129 (23 worldwide citation)

The present invention provides a compound of formula I: or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3 mammalian protein kinase. The invention also provides pharmaceutically acceptable compositions comprising th ...